AstraZeneca PLC (LON:AZN - Get Free Report) reached a new 52-week low during trading on Wednesday . The stock traded as low as GBX 9,641 ($126.14) and last traded at GBX 9,656 ($126.34), with a volume of 99590781 shares changing hands. The stock had previously closed at £103.74 ($135.73).
Analysts Set New Price Targets
Several equities analysts have recently weighed in on the stock. Berenberg Bank reiterated a "buy" rating and issued a GBX 140 ($1.83) target price on shares of AstraZeneca in a research note on Wednesday, March 26th. JPMorgan Chase & Co. reiterated an "overweight" rating on shares of AstraZeneca in a research note on Wednesday, February 19th. Finally, Shore Capital restated a "buy" rating on shares of AstraZeneca in a research report on Friday, March 7th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of GBX 6,303.50 ($82.47).
Read Our Latest Report on AstraZeneca
AstraZeneca Stock Up 3.1 %
The company's 50 day simple moving average is £114.44 and its 200-day simple moving average is £111.13. The company has a debt-to-equity ratio of 73.83, a quick ratio of 0.59 and a current ratio of 0.93. The firm has a market capitalization of £198.56 billion, a PE ratio of 28.29, a PEG ratio of 0.86 and a beta of 0.17.
About AstraZeneca
(
Get Free Report)
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
See Also
Before you consider AstraZeneca, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.
While AstraZeneca currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
